The Efficacy of Zinc as Adjunct Therapy in the Treatment of Severe Pneumonia in Children

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Pneumonia is a leading cause of morbidity and mortality in children in developing countries. Zinc deficiency leads to impairment in tissue repair and immunodeficiency in children.At least two randomised controlled trials have shown that zinc supplementation improves the outcome of severe pneumonia in children (reducing duration of hospital stay and complications related to pneumonia).

However, there are conflicting results from other randomised controlled trials about its efficacy in children with pneumonia.The purpose of the current study is to determine the efficacy of zinc as adjunct therapy for in severe pneumonia in children aged 6-59 months. We hypothesize that the proportion of children who recover from severe pneumonia following zinc adjunct therapy [(10 mg once daily for seven days) for children aged <12 months and 20 mg daily for children aged ≥12 months]will be higher than the proportion of children who recover from placebo therapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Makerere University
• Treatments: Zinc

Criteria

Inclusion Criteria:

• Children aged 6- 59 months with cough, difficult breathing and chest indrawing

• Written informed consent from the caretaker

Exclusion Criteria:

• Children with known heart disease

• Children on medication with Zinc supplements

• Children with obstructive air way disease

• Children with active measles

• Known intolerance or allergy to zinc or zinc-containing products